Apitope is a European biotech company focused on the discovery and development of revolutionary disease modifying therapies for autoimmune and allergic diseases, including multiple sclerosis, Graves’ disease, FVIII intolerance and uveitis.

Apitope’s mission is to develop novel therapeutics that directly target the underlying cause of allergy and autoimmune disease.
Our approach is unique in restoring the natural balance of the immune system with highly selective peptides that exert their effects directly.

The Apitope approach does NOT broadly suppress the immune system, allowing patients to enjoy a normal quality of life without the risk of secondary infection and further complications.

Apitope peptide therapies are identified using our patented discovery platform. This has allowed us to build an impressive pipeline of candidate therapeutics, the most advanced of which is currently undergoing early clinical trials in patients as a treatment for multiple sclerosis.
We have forged partnerships with investors and pharmaceutical companies worldwide pushing forward the development of potentially life changing therapies as quickly and efficiently as possible.

Latest News

  • Apitope regains global rights to its novel treatment for multiple sclerosis from Merck KGaA, Darmstadt, Germany.

    Chepstow, UK and Hasselt, Belgium: October 17 2016 − Apitope is a drug discovery and development company focused on highly selective therapies that reinstate immune tolerance and thereby treat the underlying cause of autoimmune, as well as allergic diseases. Today Apitope announces it has regained global rights to its compound, ATX-MS-1467, a potentially disease-modifying therapy for the treatment of Multiple Sclerosis (MS). Under the agreement with Merck KGaA, Darmstadt, Germany, Apitope will regain all rights and clinical data associated with its compound ATX-MS-1467, which just completed a Phase II clinical trial. Dr Keith Martin, CEO of Apitope, commented: “We believe ATX-MS-1467 has enormous potential for treating MS patients. We are pleased to be regaining the rights to the compound, as well as the clinical data. This will provide us with greater flexibility and control in the clinical development of ATX-MS-1467. We are now able to pursue new business collaborations to enable the further development of this promising treatment. We appreciate the efforts made by the Merck KGaA, Darmstadt, Germany -team members in advancing this programme to date." ATX-MS-1467 has successfully completed a Phase I clinical trial in six patients with secondary progressive MS (SPMS) and a second Phase I trial in 43 relapsing MS patients, assessing safety as well as biological parameters. Examination of the MRI results (new gadolinium- and total gadolinium-enhancing [Gd+] lesions) demonstrated a decrease of 78% in the number of Gd+ brain lesions in patients with relapsing MS treated with intradermal injection of ATX-MS-1467. Enrolment in a Phase IIa clinical trial of ATX-MS-1467 in Relapsing Multiple Sclerosis was completed in mid-2015, and the outcome of the study is expected Q4 2016. The terms of the agreement are not disclosed.

    Read More

  • Apitope awarded venture capital deal of the year at Wales dealmakers awards 2016

    Cardiff, UK and Hasselt, Belgium: 27th September 2016 − Apitope, the drug discovery and development company focused on treating the underlying cause of autoimmune diseases, is pleased to announce it has won the “Venture Capital Deal of the Year” Award at the Wales Dealmakers Awards 2016 for its €12 million fundraising in September 2015. The series B funding was led by Wales Life Sciences Investment Fund which brought the company to Wales where it is now conducting clinical trials. Apitope was referred to as “a game changer” in the biotechnology industry by one of the judges on the panel. Dr Keith Martin, CEO of Apitope, commented: “We are very pleased to have been awarded “Venture Capital Deal of the Year”. Apitope’s innovative discovery platform enables the discovery and development of revolutionary disease-modifying therapies for the treatment of autoimmune and allergic diseases. We have a pipeline of seven programmes in clinical and preclinical development for the treatment of multiple sclerosis, Graves’ disease, Factor VIII intolerance and uveitis.” The Venture Capital Deal of the Year is awarded to the most impressive deal involving funds from a venture capital or private equity firm to finance or acquire a company in Wales between 1 July 2015 and 30 June 2016. It must have a Wales-based business at its heart. Held at the Cardiff Marriott Hotel, the event was attended by close to 250 of the country's top dealmakers.

    Read More

Upcoming Events

  • Bio-Europe 2016, 7th-9th November – Cologne, Germany

    Our commercial director and general counsel, Dr. Hayley French and research director, Dr Lotta Jansson will be participating in the Bio-Europe partnering conference to be held November 7th – 9th in Cologne, Germany. They look forward to meeting with you to discuss potential partnerships.

    Read More